Recombinant T-cell receptor ligands in the treatment of uveitis

JAMA Ophthalmology

Volumn 131, Issue 3, 2013, Pages 399-400

  Zarbin, Marco A ^a  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD28 ANTIGEN; CD8 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EPITOPE; HLA DR3 ANTIGEN; INFLIXIMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RETINA S ANTIGEN; RETINOID BINDING PROTEIN; T LYMPHOCYTE RECEPTOR; TACROLIMUS;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; CELL INTERACTION; CELL MIGRATION; CELL SURFACE; CELLULAR IMMUNITY; CYTOKINE RELEASE; DISEASE COURSE; DRUG EFFICACY; ENDOPLASMIC RETICULUM; HUMAN; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATORY CELL; LYMPHOCYTE FUNCTION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SHORT SURVEY; T LYMPHOCYTE ACTIVATION; TH17 CELL; UVEITIS;

HUMANS; IMMUNOTHERAPY; LIGANDS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; UVEITIS;

EID: 84875208039     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.111     Document Type: Short Survey

References (10)

1. Kyger M, Worley A, Huan J, et al. Effective arrestin-specific immunotherapy of experimental autoimmune uveitis with RTL: a prospect for treatment of human uveitis. Transl Vis Sci Technol. 2013;2:1-15.
2. Caspi RR, Roberge FG, Chan CC, et al. A new model of autoimmune disease: experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol. 1988;140(5):1490-1495.
3. Mochizuki M, Kuwabara T, McAllister C, Nussenblatt RB, Gery I. Adoptive transfer of experimental autoimmune uveoretinitis in rats: immunopathogenic mechanisms and histologic features. Invest Ophthalmol Vis Sci. 1985;26(1):1-9.
4. Rizzo LV, Silver P, Wiggert B, et al. Establishment and characterization of a murine CD4+ T cell line and clone that induce experimental autoimmune uveoretinitis in B10.A mice. J Immunol. 1996;156(4):1654-1660.
5. Xu H, Rizzo LV, Silver PB, Caspi RR. Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis. Cell Immunol. 1997;178 (1):69-78.
6. Sonoda KH, Yoshimura T, Takeda A, Ishibashi T, Hamano S, Yoshida H. WSX-1 plays a significant role for the initiation of experimental autoimmune uveitis. Int Immunol. 2007;19(1):93-98.
7. Amadi-Obi A, Yu CR, Liu X, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007;13 (6):711-718.
8. Offner H, Sinha S, Burrows GG, Ferro AJ, Vandenbark AA. RTL therapy for multiple sclerosis: a phase I clinical study. J Neuroimmunol. 2011;231(1-2): 7-14.
9. Adamus G, Burrows GG, Vandenbark AA, Offner H. Treatment of autoimmune anterior uveitis with recombinant TCR ligands. Invest Ophthalmol Vis Sci. 2006; 47(6):2555-2561.
10. Adamus G, Karren LJ, Mooney J, Burrows GG. A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis. Ophthalmic Res. 2010;44(1):24-33.